MarginsXMarginsX
Home › Markets › Health Care › NRSN

NeuroSense Therapeutics Ltd. (NRSN)

NRSN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.56
-7.40% on the day
Market cap
$3.0M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerNRSN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2021
SEC CIK0001875091
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
0.3 months
$166K cash at December 31, 2025
Share count, 1 year
+40.2%
2024-12-31 to 2025-12-31
Going-concern doubt
Yes
20-F filed March 31, 2026
Insider net buying, 12 months
$200K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
20-F 2026-03-31
Cash and burn$166K cash; operating cash flow -$1.9M a quarter.Report 2025-12-31
Shares outstanding1,627,859 (2025-12-31); 23,228,941 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-20 on 2026-09-14Source 2026-09-14
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorSomekh Chaikin, Tel Aviv, IsraelPCAOB Form AP 2026-05-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $200K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$11.1M-$7.7M$166KNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2024
2024-12-31
Not filed-$10.2M-$10.1M$3.4MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2023
2023-12-31
Not filed-$10.1M-$8.4M$2.6MNo debt tagsNeeds four quarters20-F 2026-03-31
FY 2022
2022-12-31
Not filed-$10.5M-$7.6M$3.5MNo debt tagsNeeds four quarters20-F 2025-04-07
FY 2021
2021-12-31
Not filed-$4.0M-$1.5M$11.1MNo debt tagsNeeds four quarters20-F 2024-04-04
FY 2020
2020-12-31
Not filed-$2.8M-$695K$699KNo debt tagsNeeds four quarters20-F 2023-03-22
FY 2019
2019-12-31
Not filed-$1.2M-$582K$895KNo debt tagsNeeds four quarters20-F 2022-04-14

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
F-32026-01-29
Latest annual report
ANNUAL REPORT
20-F2026-03-31
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-02

Source: SEC EDGAR submissions feed, 314 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.6%
1 month-51.6%
3 months-80.9%
Year to date-89.0%
1 year-90.8%
From 52-week high-93.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
NRSNWNeuroSense Therapeutics Ltd. Warrant$0.0055

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M
GRIGRI Bio Inc.$1.40-18.60%$3.1M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M
RDHLRedhill Biopharma Ltd.$0.3605-3.87%$3.2M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier